Acorda Therapeutics, Inc. (NASDAQ:ACOR) has been given an average rating of “Hold” by the nineteen analysts that are currently covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $21.47.
Several equities analysts recently weighed in on the stock. Cowen restated a “buy” rating and set a $35.00 price target on shares of Acorda Therapeutics in a research report on Tuesday, August 29th. Stifel Nicolaus restated a “buy” rating and set a $26.00 price target (down previously from $30.00) on shares of Acorda Therapeutics in a research report on Thursday, August 31st. HC Wainwright assumed coverage on shares of Acorda Therapeutics in a research report on Wednesday, November 8th. They set a “buy” rating and a $35.00 price target for the company. TheStreet lowered shares of Acorda Therapeutics from a “c-” rating to a “d+” rating in a research report on Friday, November 17th. Finally, J P Morgan Chase & Co set a $24.00 price target on shares of Acorda Therapeutics and gave the company a “hold” rating in a research report on Tuesday, October 31st.
In other news, insider Burkhard Blank sold 11,050 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $20.53, for a total value of $226,856.50. Following the completion of the transaction, the insider now directly owns 33,150 shares in the company, valued at $680,569.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.90% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in ACOR. State Street Corp boosted its stake in Acorda Therapeutics by 52.4% during the second quarter. State Street Corp now owns 2,476,033 shares of the biopharmaceutical company’s stock worth $48,783,000 after buying an additional 851,290 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Acorda Therapeutics by 29.6% during the second quarter. Dimensional Fund Advisors LP now owns 2,372,868 shares of the biopharmaceutical company’s stock valued at $46,745,000 after purchasing an additional 541,418 shares during the last quarter. RA Capital Management LLC grew its stake in shares of Acorda Therapeutics by 83.8% during the second quarter. RA Capital Management LLC now owns 900,259 shares of the biopharmaceutical company’s stock valued at $17,735,000 after purchasing an additional 410,431 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Acorda Therapeutics by 306.8% during the second quarter. Goldman Sachs Group Inc. now owns 534,956 shares of the biopharmaceutical company’s stock valued at $10,538,000 after purchasing an additional 403,467 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of Acorda Therapeutics by 65.2% during the second quarter. Northern Trust Corp now owns 897,974 shares of the biopharmaceutical company’s stock valued at $17,690,000 after purchasing an additional 354,304 shares during the last quarter.
Shares of Acorda Therapeutics (NASDAQ:ACOR) traded down $0.10 during mid-day trading on Friday, hitting $20.35. 372,100 shares of the stock traded hands, compared to its average volume of 932,747. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.77 and a quick ratio of 2.40. Acorda Therapeutics has a 52 week low of $13.60 and a 52 week high of $33.00.
Acorda Therapeutics (NASDAQ:ACOR) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.43 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.69 by ($0.26). The firm had revenue of $141.07 million during the quarter, compared to analysts’ expectations of $150.64 million. Acorda Therapeutics had a negative net margin of 10.25% and a negative return on equity of 8.18%. The business’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.04) EPS. equities research analysts anticipate that Acorda Therapeutics will post -0.07 earnings per share for the current fiscal year.
WARNING: This article was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://ledgergazette.com/2017/12/06/acorda-therapeutics-inc-acor-receives-consensus-rating-of-hold-from-analysts.html.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.